Cetera Investment Advisers Buys 561 Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Cetera Investment Advisers boosted its position in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 2.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,893 shares of the company’s stock after acquiring an additional 561 shares during the period. Cetera Investment Advisers owned approximately 0.69% of Invesco Biotechnology & Genome ETF worth $1,808,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in PBE. Ashton Thomas Private Wealth LLC bought a new stake in Invesco Biotechnology & Genome ETF in the second quarter valued at about $26,000. GPS Wealth Strategies Group LLC bought a new position in shares of Invesco Biotechnology & Genome ETF during the 2nd quarter worth approximately $30,000. UMB Bank n.a. acquired a new stake in Invesco Biotechnology & Genome ETF in the 2nd quarter valued at $31,000. Covestor Ltd grew its position in Invesco Biotechnology & Genome ETF by 24.2% in the first quarter. Covestor Ltd now owns 955 shares of the company’s stock valued at $62,000 after acquiring an additional 186 shares during the period. Finally, B. Riley Wealth Advisors Inc. acquired a new position in Invesco Biotechnology & Genome ETF during the first quarter worth $232,000.

Invesco Biotechnology & Genome ETF Price Performance

PBE stock opened at $69.96 on Tuesday. The business has a fifty day moving average price of $69.84 and a 200 day moving average price of $66.46. Invesco Biotechnology & Genome ETF has a fifty-two week low of $52.47 and a fifty-two week high of $72.72. The stock has a market capitalization of $282.66 million, a price-to-earnings ratio of 17.12 and a beta of 0.88.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.